

avacopan (TAVNEOS)

Diagnoses Considered for Coverage:

- ANCA-associated vasculitis

Coverage Criteria:

1. **For diagnosis of ANCA-associated vasculitis (granulomatosis with polyangiitis [GPA]/ Wegener's granulomatosis and microscopic polyangiitis [MPA]):**
 - Being used in combination with standard therapy (e.g. glucocorticosteroids, cyclophosphamide, or rituximab), **and**
 - Dose does not exceed 60 mg daily.

Coverage Duration: one year

Effective Date: 03/02/2022